INSIGHT - Post Marketing Surveillance
In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment under daily-life treatment conditions. Specifically investigated are the tumor status, prior and/ or concomitant surgical, radiological and drug treatment and the duration of Sorafenib treatment.
Carcinoma, Hepatocellular
DRUG: Sorafenib (Nexavar, BAY43-9006)
Efficacy: status of tumor, patients performance status, At each follow-up visit, every 2-4 months
Duration of treatment, At each follow-up visit, every 2-4 months|Time of survival, At each follow-up visit, every 2-4 months|Reports of adverse events, At each follow-up visit, every 2-4 months
In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment under daily-life treatment conditions. Specifically investigated are the tumor status, prior and/ or concomitant surgical, radiological and drug treatment and the duration of Sorafenib treatment.